Back to Clinical Trials

Brief Title: TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

INTRODUCTION

  • Org Study ID: 17000139BLC3004
  • Secondary ID: N/A
  • NCT ID: NCT06211764
  • Sponsor: Janssen Research & Development, LLC

BRIEF SUMMARY

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) within 1 year of last dose of Bacillus Calmette-Guérin (BCG) therapy and who refused or are unfit for Radical Cystectomy (RC), receiving TAR-200 versus investigator's choice of single agent intravesical chemotherapy.

  • Overall Status
    Recruiting
  • Start Date
    April 9, 2024
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Disease-free Survival (DFS)

Primary Outcome 1 - Timeframe: Up to 6 years 7 months

CONDITION

  • Non-Muscle Invasive Bladder Neoplasms

ELIGIBILITY

Inclusion Criteria:
* Histologically confirmed diagnosis by local pathology (within 90 days of documented informed consent) of recurrent, papillary-only high-risk non-muscle-invasive bladder cancer (HR-NMIBC) [defined as high-grade Ta or any T1, no carcinoma in situ (CIS)]

- * Participants with variant histologic subtypes are allowed if tumor(s) demonstrate urothelial (transitional cell histology) predominance. However, neuroendocrine, and small cell variants will be excluded

- * Participants must be ineligible for or have elected not to undergo Radical Cystectomy (RC)

- * Have an Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0, 1, or 2
Exclusion Criteria:
* Presence of CIS at any point from time of diagnosis of papillary-only HR-NMIBC recurrence to randomization. Additionally, presence or history of histologically confirmed, muscle-invasive, locally advanced, nonresectable, or metastatic urothelial carcinoma (that is, T2, T3, T4, N+, and/or M+)

- * Presence of any bladder or urethral anatomic feature that, in the opinion of the Investigator, may prevent the safe placement, indwelling use, or removal of TAR-200. Participants with tumors involving the prostatic urethra in men will be excluded

- * A history of clinically significant polyuria with recorded 24-hour urine volumes greater than 4000 milliliters (>4000 mL)

- * Indwelling catheters are not permitted; however, intermittent catheterization is acceptable

- * Previous treatment with TAR-200

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Janssen Research & Development, LLC Clinical trial

Role: Study Director

Affiliation: Janssen Research & Development, LLC

Overall Contact

Name: Study Contact

Phone: 844-434-4210

Email: [email protected]

LOCATION

Facility Status Contact
Facility: Arkansas Urology
Little Rock, Arkansas 72211
United States
Status: Recruiting Contact: N/A
Facility: Genesis Research LLC
Los Alamitos, California 90720
United States
Status: Recruiting Contact: N/A
Facility: USC Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: N/A
Facility: University of California Irvine Medical Center
Orange, California 92868
United States
Status: Recruiting Contact: N/A
Facility: University of California San Francisco
San Francisco, California 94158 2549
United States
Status: Recruiting Contact: N/A
Facility: Genesis Research LLC
Torrance, California 90503
United States
Status: Recruiting Contact: N/A
Facility: Colorado Clinical Research
Lakewood, Colorado 80228
United States
Status: Recruiting Contact: N/A
Facility: Florida Urology Partners
Riverview, Florida 33578
United States
Status: Recruiting Contact: N/A
Facility: UroPartners
Chicago Ridge, Illinois 60415
United States
Status: Recruiting Contact: N/A
Facility: Northwestern University
Chicago, Illinois 60611
United States
Status: Recruiting Contact: N/A
Facility: Urology of Indiana
Carmel, Indiana 46032
United States
Status: Recruiting Contact: N/A
Facility: First Urology, PSC
Jeffersonville, Indiana 47130
United States
Status: Recruiting Contact: N/A
Facility: Wichita Urology Group
Wichita, Kansas 67226
United States
Status: Recruiting Contact: N/A
Facility: Comprehensive Urology
Royal Oak, Michigan 48073
United States
Status: Recruiting Contact: N/A
Facility: Specialty Clinical Research of St Louis
Saint Louis, Missouri 63141
United States
Status: Recruiting Contact: N/A
Facility: Associated Medical Professionals
Syracuse, New York 13210
United States
Status: Recruiting Contact: N/A
Facility: The Urology Group
Cincinnati, Ohio 45212
United States
Status: Recruiting Contact: N/A
Facility: Central Ohio Urology Group
Gahanna, Ohio 43230
United States
Status: Recruiting Contact: N/A
Facility: Centers for Advanced Urology LLC d b a MidLantic Urology
Bala-Cynwyd, Pennsylvania 19004
United States
Status: Recruiting Contact: N/A
Facility: Ralph H. Johnson Veterans Affairs Medical Center
Charleston, South Carolina 29401
United States
Status: Recruiting Contact: N/A
Facility: Carolina Urologic Research Center
Myrtle Beach, South Carolina 29572
United States
Status: Recruiting Contact: N/A
Facility: Low Country Urology Clinics
North Charleston, South Carolina 29406
United States
Status: Recruiting Contact: N/A
Facility: Urology Associates
Nashville, Tennessee 37209
United States
Status: Recruiting Contact: N/A
Facility: Vanderbilt University Medical Center
Nashville, Tennessee 37232
United States
Status: Recruiting Contact: N/A
Facility: Urology Austin
Austin, Texas 78745
United States
Status: Recruiting Contact: N/A
Facility: Urology Clinics of North Texas
Dallas, Texas 75231
United States
Status: Recruiting Contact: N/A
Facility: University of Texas Southwestern Medical Center
Dallas, Texas 75390
United States
Status: Recruiting Contact: N/A
Facility: Houston Metro Urology
Houston, Texas 77027
United States
Status: Recruiting Contact: N/A
Facility: Spokane Urology
Spokane, Washington 99202
United States
Status: Recruiting Contact: N/A